BioSpace News Archive

University of Minnesota Masonic Children’s Hospital announced earlier as one of the three pillar charities

Insmed Incorporated announced the closing of the previously announced public offering of its common stock.

Jakafi is the first and only FDA-approved treatment for patients with steroid-refractory acute graft-versus-host disease (GVHD)

The U.S. Food and Drug Administration approved Piqray tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

Ahead of the holiday, American Addiction Centers reminds people to keep their sober friends in mind during their weekend gatherings.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics announced that Aron Knickerbocker, Chief Executive Officer, is scheduled to present at the following two investor conferences:

Immunomic Therapeutics, Inc. announced that the company will present at the 5th Annual Immuno-oncology BD&L and Investment Forum being held in Chicago, IL, May 31, 2019.

Novartis announced the US FDA has approved Piqray® in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-), PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test following progression on or after an endocrine-based regimen

BridgeBio Pharma, Inc. announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock.

The Muscular Dystrophy Association celebrated the decision by the U.S. Food and Drug Administration to grant approval of Zolgensma, the first gene therapy for a neuromuscular disease.